Antispasmodics Drugs Market 2024-2033: Size, Share & Competitive Landscape Analysis

The antispasmodics drugs market size has grown strongly in recent years. It will grow from $12.69 billion in 2023 to $13.92 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rising prevalence of spasmodic conditions, advancements in medical research, growing aging population, changing lifestyles, improvements in diagnosis.

The antispasmodics drugs market size is expected to see strong growth in the next few years. It will grow to $20.04 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing healthcare expenditure, personalized medicine, global population growth, emerging markets, clinical trials and research. Major trends in the forecast period include expanding indications for antispasmodics, healthcare infrastructure development, advancements in drug development, increasing awareness and diagnosis, preference for non-invasive treatment options.

Market Overview -
Antispasmodic drugs are medications that treat, prevent, or reduce the frequency of muscular spasms, particularly those of smooth muscle, such as those in the gut wall. It works by slowing the normal motions of the gut and relaxing the muscles of the stomach and intestines.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9414&type=smp

Elderly Population Boom Fuels Growth In Antispasmodic Drug Market
An increasing elderly population is expected to propel the growth of the antispasmodic drug market going forward. People of 65 years and older are considered to be elderly and are associated with a host of physical and psychological health issues. Antispasmodic drugs are helpful for elderly populations in managing symptoms related to various conditions that can cause muscle spasms or cramping and also could be used for some conditions like irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. For instance, in October 2022, according to the World Health Organization (WHO), a Switzerland-based organization responsible for international public health, the global proportion of the population aged 60 and up will rise to 1.4 billion in 2030. The world's population of persons aged 60 and over will double by 2050 (2.1 billion). The number of people aged 80 or more is predicted to increase substantially by 2050, reaching 426 million. Therefore, an increase in the elderly population will drive the antispasmodic drug market.

Competitive Landscape -
Major companies operating in the antispasmodics drugs market report are Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd. .

Product Innovation Transforms The Market
Product innovations are a key trend in gaining popularity in the antispasmodic drugs market. Major companies operating in the antispasmodic drugs market are focused on developing innovative solutions to strengthen their position in the market. For instance, in April 2022, Ardelyx Inc., a US-based biopharmaceutical firm, announced the introduction of IBSRELA, an NHE-3 inhibitor used to treat individuals with irritable bowel syndrome with constipation (IBS-C). The product offers a unique new therapeutic option with a novel mode of action and remarkable effective results to address constipation and numerous abdominal symptoms typical in IBS-C patients, as established in Phase 3 clinical studies.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/antispasmodics-drugs-global-market-report

Key Segments -
The antispasmodics drugs market covered in this report is segmented -
1) By Drug: Dicyclomine Hydrochloride, Loperamide Hydrochloride, Other Drugs
2) By Indication: Irritable Bowel Syndrome, Stomach Cramps, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Modes Of Administrations
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmnacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.